98 related articles for article (PubMed ID: 18300479)
1. [Preparation and in vitro tumor cells selectivity of sterically stabilized immunoliposomal peptides in bee venom].
Hu HY; Chen DW; Liu YF; Qiao MX; Zhao XL
Yao Xue Xue Bao; 2007 Nov; 42(11):1201-5. PubMed ID: 18300479
[TBL] [Abstract][Full Text] [Related]
2. Preparation and targeted delivery of immunoliposomes bearing poly(ethylene glycol)-coupled humanized anti-hepatoma disulfide-stabilized Fv (hdsFv25) in vitro.
Hu H; Chen D; Liu Y; Deng Y; Yang S; Qiao M; Zhao J; Zhao X
Pharmazie; 2006 Aug; 61(8):685-8. PubMed ID: 16964711
[TBL] [Abstract][Full Text] [Related]
3. Target ability and therapy efficacy of immunoliposomes using a humanized antihepatoma disulfide-stabilized Fv fragment on tumor cells.
Hu H; Chen D; Liu Y; Deng Y; Yang S; Qiao M; Zhao J; Zhao X
J Pharm Sci; 2006 Jan; 95(1):192-9. PubMed ID: 16315243
[TBL] [Abstract][Full Text] [Related]
4. Effect of polypeptides in bee venom on growth inhibition and apoptosis induction of the human hepatoma cell line SMMC-7721 in-vitro and Balb/c nude mice in-vivo.
Hu H; Chen D; Li Y; Zhang X
J Pharm Pharmacol; 2006 Jan; 58(1):83-9. PubMed ID: 16393467
[TBL] [Abstract][Full Text] [Related]
5. Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes.
Lopez-Barcons LA; Polo D; Reig F; Fabra A
J Biomed Mater Res A; 2004 Apr; 69(1):155-63. PubMed ID: 14999763
[TBL] [Abstract][Full Text] [Related]
6. Preparation and in vitro targeting of sterically stabilized liposomes modified with chimeric TNT-3 monoclonal antibody.
Pan H; Niu GQ; Pan J; Lu WY
Yao Xue Xue Bao; 2006 Jun; 41(6):506-12. PubMed ID: 16927823
[TBL] [Abstract][Full Text] [Related]
7. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
8. Liposomes modified with YIGSR peptide for tumor targeting.
Dubey PK; Singodia D; Vyas SP
J Drug Target; 2010 Jun; 18(5):373-80. PubMed ID: 20020817
[TBL] [Abstract][Full Text] [Related]
9. Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes.
Derycke AS; De Witte PA
Int J Oncol; 2002 Jan; 20(1):181-7. PubMed ID: 11743662
[TBL] [Abstract][Full Text] [Related]
10. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).
Atobe K; Ishida T; Ishida E; Hashimoto K; Kobayashi H; Yasuda J; Aoki T; Obata K; Kikuchi H; Akita H; Asai T; Harashima H; Oku N; Kiwada H
Biol Pharm Bull; 2007 May; 30(5):972-8. PubMed ID: 17473445
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
13. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting.
Terada T; Iwai M; Kawakami S; Yamashita F; Hashida M
J Control Release; 2006 Apr; 111(3):333-42. PubMed ID: 16488046
[TBL] [Abstract][Full Text] [Related]
14. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.
Rege K; Patel SJ; Megeed Z; Yarmush ML
Cancer Res; 2007 Jul; 67(13):6368-75. PubMed ID: 17616696
[TBL] [Abstract][Full Text] [Related]
15. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor.
Manjappa AS; Chaudhari KR; Venkataraju MP; Dantuluri P; Nanda B; Sidda C; Sawant KK; Murthy RS
J Control Release; 2011 Feb; 150(1):2-22. PubMed ID: 21095210
[TBL] [Abstract][Full Text] [Related]
16. Lasioglossins: three novel antimicrobial peptides from the venom of the eusocial bee Lasioglossum laticeps (Hymenoptera: Halictidae).
Cerovský V; Budesínský M; Hovorka O; Cvacka J; Voburka Z; Slaninová J; Borovicková L; Fucík V; Bednárová L; Votruba I; Straka J
Chembiochem; 2009 Aug; 10(12):2089-99. PubMed ID: 19591185
[TBL] [Abstract][Full Text] [Related]
17. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
Demirgöz D; Garg A; Kokkoli E
Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
[TBL] [Abstract][Full Text] [Related]
18. Contribution of linker stability to the activities of anticancer immunoconjugates.
Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
[TBL] [Abstract][Full Text] [Related]
19. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Hong M; Zhu S; Jiang Y; Tang G; Pei Y
J Control Release; 2009 Jan; 133(2):96-102. PubMed ID: 18840485
[TBL] [Abstract][Full Text] [Related]
20. Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.
Kawano K; Onose E; Hattori Y; Maitani Y
Mol Pharm; 2009; 6(1):98-104. PubMed ID: 19072653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
